Alligator Bioscience AB (OSTO:ATORX) Beta: 3.9447 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ATORX Alligator Bioscience AB OSTO:ATORX
39 GF Score
Price kr0.17
GF Value kr0.01
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Alligator Bioscience AB Beta?

Alligator Bioscience AB OSTO:ATORX -3.60% 39 Beta is 3.9447 as of Jul. 14, 2026. GuruFocus rates OSTO:ATORX with a GF Score™ of 39/100 and a GF Value™ of kr0.01 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-14), Alligator Bioscience AB's Beta is 3.9447.


Alligator Bioscience AB  (OSTO:ATORX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Alligator Bioscience AB Beta Related Terms


Alligator Bioscience AB Beta Historical Data

* Premium members only.

The historical data trend for Alligator Bioscience AB's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alligator Bioscience AB Beta Chart

Alligator Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.04 1.09 1.75 1.96 5.46

Alligator Bioscience AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.21 4.47 5.22 5.46 3.95

OSTO:ATORX vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Alligator Bioscience AB's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alligator Bioscience AB Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Beta distribution charts can be found below:

* The bar in red indicates where Alligator Bioscience AB's Beta falls into.


OSTO:ATORX
39GF Score
Alligator Bioscience AB OSTO:ATORX
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alligator Bioscience AB Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 3.9447 mean?
Alligator Bioscience AB (OSTO:ATORX) has a Beta of 3.9447 as of Jul. 14, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Alligator Bioscience AB and its competitors.
Is Alligator Bioscience AB's Beta too high?
Alligator Bioscience AB's current Beta is 3.9447. Overall, Alligator Bioscience AB has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alligator Bioscience AB's Beta compare to VRTX and REGN?
Alligator Bioscience AB's Beta of 3.9447 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Alligator Bioscience AB and its competitors. Alligator Bioscience AB's current Beta is 3.9447. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Alligator Bioscience AB (OSTO:ATORX) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.01, compared to a current price of kr0.17 — trading 1612% above its estimated fair value. The current Beta is 3.9447. Alligator Bioscience AB's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Alligator Bioscience AB (OSTO:ATORX), the current Beta is 3.9447 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alligator Bioscience AB (OSTO:ATORX) Overvalued in 2026?

Based on GuruFocus' analysis, Alligator Bioscience AB stock appears to be overvalued. The current stock price of kr0.17 is trading 1612% above its estimated GF Value™ of kr0.01. GuruFocus considers Alligator Bioscience AB to be Significantly Overvalued.

Key valuation signals for OSTO:ATORX:

  • Beta: 3.9447
  • GF Value™: kr0.01 vs. price of kr0.17 (1612% above fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the OSTO:ATORX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alligator Bioscience AB Business Description

Other Exchanges 0RK9:UK7AL0:Germany
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
39GF Score

Get the complete analysis for OSTO:ATORX

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.17
Price
kr0.01
GF Value